NVP-BHG712

Research use only, not for human use.

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition.

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

——

Animal Model:Mice arrying chambers.Dosage:3, 10 and 30 mg/kg.Administration:P.O. daily for 4 days.Result:Significantly inhibited VEGF stimulated tissue formation and vascularization at doses of daily 3 mg/kg. Administration of 10 mg/kg/kg p.o. was sufficient to reverse VEGF enhanced tissue formation and vessel growth.

NVP BHG712 | NVP BHG-712 | NVP BHG 712 | BHG-712 | BHG712

Tyrosine Kinase

Ephrin Receptor

EphB4

Cancer

——

940310-85-0

503.489

C26H20F3N7O

>98% (HPLC)

10 mM in DMSO

O=C(NC1=CC=CC(C(F)(F)F)=C1)C2=CC=C(C)C(NC3=C4C(N(C)N=C4)=NC(C5=CC=CN=C5)=N3)=C2

4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide

(-20℃)

With Ice Pack

≥ 2 years